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INTRODUCTION
Urinary tract infection (UTI) is a common cause of morbid-
ity and mortality, especially in women, with 25% to 30% of
20 to 40-yr-old women reporting a history of UTI treatment.
Escherichia coli is by far the most common bacterial pathogen
in UTI, accounting for more than 85% of cases of acute cys-
titis and pyelonephritis as well as for more than 60% of cases
of recurrent cystitis (1). 
The significant socioeconomic implications of UTI have
generated considerable interest in the prevention of recur-
rences. Although long-term, low-dose antibiotic prophylax-
is (e.g. trimethoprim-sulfamethoxazole) has been demonstrat-
ed to be highly effective in reducing the risk of recurrent UTI,
repeated use of antibiotics has led to bacterial resistance. Other
prospects for UTI prophylaxis include natural compounds,
bacterial interference and immunization (2). The most com-
monly used natural compound appears to be cranberry juice.
In a double-blind, randomized, controlled study, daily inges-
tion of 300 mL of cranberry juice reduced bacteriuria with
pyuria but failed to decrease the incidence of symptomatic
UTIs (3). The concept of bacterial interference is based on not
treating asymptomatic colonization, such that ‘‘good’’ bacte-
ria prevent symptomatic UTI caused by ‘‘bad’’ bacteria. There
have been provocative data suggesting non-treatment in pati-
ent populations with a high prevalence of asymptomatic bac-
teriuria, including the elderly, school girls and patients with
spinal cord injury (4-7), but lack of information on the strains
causing asymptomatic colonization in these patient popula-
tions is a major limitation of this concept. Immunotherapy
may therefore represent the most effective alternative in the
prevention of recurrent UTI. For example, oral immunization
with E. coli extract (ECE; Uro-Vaxom
�, OM Laboratories Mey-
rin/Geneva, Switzerland), a combination of immunoactive
fractions of E. coli strains, has gained popularity, primarily in
European countries. Administration of a lyophilized extract of
18 uropathogens has been found to increase non-specific and
specific humoral and cellular immune responses by stimulat-
ing the production of interferon-g and tumor necrosis factor-g
and the activities of lymphocytes and macrophages (8-10).
Although clinical trials of ECE commenced as early as 1980
(11, 12), these studies focused on its efficacy during and for
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A Prospective Multi-center Trial of Escherichia coli Extract for the
Prophylactic Treatment of Patients with Chronically Recurrent Cystitis
We have assessed the efficacy and safety of Escherichia coli extract (ECE; Uro-
Vaxom
�) which contains active immunostimulating fractions, in the prophylactic
treatment of chronically recurrent cystitis. Forty-two patients with more than 2 epi-
sodes of cystitis in the proceeding 6 months were treated for 3 months with one cap-
sule daily of ECE and observed for a further 6 months. The primary efficacy criteri-
on was the number of episodes of recurrent cystitis during the 6 months after treat-
ment compared to those during the 6 months before treatment. At the end of the 9-
month trial, 34 patients (all women) were eligible for statistical analysis. Their mean
age was 56.4 yr (range, 34-75 yr), and they had experienced recurrent urinary tract
infections for 7.2±5.2 yr. The number of recurrences was significantly lower during
the 6-month follow-up period than during the 6 months preceding the trial (0.35 vs.
4.26, P<0.001). During the follow-up, 28 (82.4%) patients had no recurrences and
4 (11.8%) had 1 each. In patients who relapsed, ECE alleviated cystitis symptoms,
including painful voiding, frequency and urgency. There were no serious adverse
events related to the study drug. Our study demonstrates the efficacy and safety
of ECE in the prophylactic treatment of chronically recurrent cystitis.
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3 months after treatment, but not for longer periods of time
(13, 14). To our knowledge, there have been no clinical stud-
ies of ECE in which patients were followed for up to 6 months
after treatment. We therefore assessed the efficacy and toler-
ability of ECE administration in the prophylactic treatment
of chronically recurrent cystitis for 6 months after treatment.
MATERIALS AND METHODS
Patients with more than 2 episodes of cystitis, defined as
≥105 c.f.u. bacteria/mL and white blood cell (WBC) ≥6/
HPF in mid-stream urine with concomitant symptoms such
as painful and irritating voiding symptoms, during the pro-
ceeding 6 months were screened, and 42 patients were en-
rolled in this multicenter prospective study. Patients with
vesicoureteral reflux, obstructive uropathy, urinary lithiasis,
renal impairment (defined as serum creatinine >2.5 mg/dL)
and urologic procedures that induced UTI were excluded.
The study protocol was approved by the institutional review
board in each hospital, and all patients provided written in-
formed consent before entry. 
At the start of the trial, all patients were in acute recurrence
and were therefore treated with antibiotics. After confirming
that their urine was sterile, patients were treated for 3 months
with one capsule daily of ECE, containing 6 mg of lyophiliz-
ed immunostimulating fractions, and observed for an addi-
tional 6 months without treatment. UTI episodes occurring
during the 6 month follow-up period were treated with per-
tinent antibiotics, and symptom severity was assessed. The
degree of urgency was assessed according to the Indevus Urgen-
cy Severity Score (IUSS), in which 0 represents no, 1 repre-
sents mild, 2 represents moderate, and 3 represents severe
urgency. Painful voiding, abdominal/flank pain and fever
were each scored according to a similar scale. Frequency was
assessed according to a 5 point scale, in which 0 represents
>3 hr, 1 <3 hr, 2 <2 hr, 3 <1 hr, and 4 <30 min. Patients
who developed UTI during ECE treatment were excluded
from the study. Blood chemistry was performed at entry and
after 3 months to monitor drug safety. Midstream urine cul-
ture and urinalysis were performed at study outset, and 3 and
9 months after the start of ECE treatment, and at any symp-
tom recurrence. At each visit, patients were questioned about
compliance and any adverse events.
The primary efficacy criterion was the number of episodes
of recurrent cystitis which was measured with the medical
record (defined by urinalysis, urine culture, and the presence
of concomitant symptoms) during the 6 months after treat-
ment compared to those during the 6 months before treat-
ment. Secondary efficacy criteria included the severity of cys-
titis symptoms, including dysuria, frequency and urgency,
in those who relapsed. Safety evaluations included compar-
isons of hepatic and renal function and adverse events before
and after treatment. 
For the determination of sample size, based on an estimat-
ed clinical efficacy rate for Uro-vaxom of 80.7% (a=0.05) (15),
the sample size was calculated to be 27 patients. Considering
an estimated 10% drop-out rate, the actual size of study popu-
lation should be at least 30 patients. Quantitative data were
expressed as mean±SD. Statistical analyses included paramet-
ric one-way ANOVA and nonparametric Wilcoxon’s matched-
pairs test. Differences were considered significant at P<0.05. 
RESULTS
Patients
Of the 42 enrolled patients, 8 were excluded, 2 for gastroin-
testinal problems such as nausea and abdominal pain, 1 for
failure to return after the first visit for reasons unrelated to
the study medication, 3 for withdrawal of consent, and 2 who
developed symptomatic UTI recurrences during ECE treat-
ment. Accordingly, 34 patients were eligible for efficacy anal-
ysis at the end of the 9-month trial. All 42 recruited patients
were included in the safety analysis. The mean age of the 34
included patients, all women, was 56.4 yr (range 34-75 yr), and
they had experienced recurrent UTIs for 7.2±5.2 yr. 
Efficacy
The number of recurrences per patient was significantly
lower during the 6 months after the end of treatment than
during the 6 months prior to treatment (0.35 vs. 4.26, P<
0.001). During follow-up, 28 patients (82.4%) had no recur-
rences and 4 (11.8%) had 1 each. In addition, one patient
(2.9%) had 2 recurrences and one (2.9%) had 6. Adminis-
tration of ECE to the 6 patients who relapsed during follow-
up alleviated cystitis symptoms, including painful voiding,
frequency and urgency (Figs. 1-3). E. coli was the organism
most frequently isolated from urine, both before (87%) and
after (50%) treatment. 
We divided the patient population into 2 subgroups: those
with ‘severe’ and ‘non-severe’ cystitis, defined as ≥6 and <6
episodes, respectively, during the 6 months preceding the trial.
Fig. 1. Changes of urgency in recurred patients (n=6).
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Of the 10 patients with ‘severe’ cystitis, only 3 (30%) expe-
rienced recurrences, compared with 3 of 24 patients (12.5%)
with ‘non-severe’ cystitis, a difference that was not statistical-
ly significant (P>0.05).
Safety
During treatment, 2 patients suffered from mild gastroin-
testinal problems: one from nausea and the other from abdom-
inal pain, each of which lasted for 1 week. These adverse events
ceased when they stopped taking the study drug, and both
patients therefore quit the trial. The remaining patients did
not complain of any discomfort, including skin pruritus and
vertigo, which had been reported in other trials of ECE. Hep-
atic and renal functions, as assessed in laboratory studies, re-
mained normal after taking ECE (Table 1).
DISCUSSION
The main therapeutic approach in UTI has been the admin-
istration of antibiotics, which is usually effective during the
acute phase. For patients with chronic or recurrent UTIs, how-
ever, repetitive intake of antibiotics, even at clinically thera-
peutic doses, may lead to the emergence of antibiotic-resis-
tant bacterial strains as well as impairment of the patient’s
natural immune defense system (16, 17). Although attempts
have been made to control or reduce the frequency of acute
exacerbations of UTI using natural compounds such as cran-
berry juice, the results have not been promising (3). In con-
trast, bacterial vaccines have been shown effective by improv-
ing the patient’s own immune response (8-10). ECE, an im-
munomodulating preparation containing the lyophilized ex-
tract of 18 uropathogens, has been shown to up-regulate the
activity of phagocytes, B-lymphocytes and natural killer cells
(8-10, 18). Animal experiments have indicated that repeat-
ed oral administration of ECE can stimulate the formation
of serum IgA and IgG in mice (19), and to activate bacterial
killing by polymorphonuclear cells in rabbits, thus enhanc-
ing the clearance of bacteria from the blood stream (20).
ECE has been utilized clinically for more than 20 yr and
has a good safety profile. At present, it is used to prevent recur-
ring UTIs in children and adults (11-14, 21, 22). Many clini-
cal trials have assessed the ability of ECE to prevent recurrent
UTIs. For example, a double-blind placebo-controlled mul-
ticenter study in 166 patients with recurrent UTIs has shown
that, during a 3-month observation period, patients on ECE
experienced significantly fewer recurrences, less severe signs
and symptoms of UTI and decreased usage of antibiotics and
chemotherapeutics compared with patients taking placebo
(14). In a second trial, in 112 patients with recurrent lower
UTIs, patients in the ECE group (n=58) experienced 65.8%
fewer episodes of UTIs than patients in the placebo group
(n=54), without any critical side effects (13). 
Subset analysis showed that only 30% of patients who expe-
rienced severe UTI, defined as ≥6 cystitis episodes before
Fig. 2. Changes of painful voiding symptom in recurred patients
(n=6).
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There was no statistically significant differences between two groups
(P>0.05).
AST, aspartate aminotransferase; ALT, alanine aminotransferase; LDH,
lactate dehydrogenase; ALP, alkaline phosphatase; BUN, blood urea
nitrogen.
Laboratory studies
Before
treatment
After
treatment
WBC (×10
3/mL) 6.3±2.1 6.0±1.8
RBC (×10
6/mL) 4.3±0.3 4.3±0.4
Hb (g/dL) 12.5±1.1 12.7±1.1
Hct (%) 38.1±3.2 39±3.1
Plt (×10
6/mL) 256±67 258±61
Neutrophils (%) 56±11.4 53.2±10.3
Lymphocytes (%) 34.3±10.2 37.5±9.1
Monocytes (%) 6.5±2.3 5.5±1.7
Eosinophils (%) 2.6±2.1 2.7±1.8
Basophils (%) 0.6±0.3 0.7±0.4
AST (IU/L) 22.7±5.9 23±6.6
ALT (IU/L) 18.5±7.7 17±7.5
LDH (IU/L) 221.5±78.5 206.5±37
ALP (IU/L) 79.2±50.3 69±30.3
Total bilirubin (mg/dL) 0.7±0.3 0.7±0.2
BUN (mg/dL) 14.1±3.8 13.7±4.5
Creatinine (mg/dL) 0.8±0.1 0.8±0.1
Table 1. Results of laboratory studies before and after E. coli ex-
tract administration
Fig. 3. Changes of frequency in recurred patients (n=6).
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the trial, experienced recurrences after treatment, a frequen-
cy that did not differ significantly from the 12.5% rate ob-
served in patients with less severe UTI (<6 episodes before
treatment). The ability of this E. coli extract to prevent recur-
rences in more recurrent patients indicates that this agent
may have greater treatment benefit in patients with more
severe UTI.
Although this was not a double-blind, placebo-controlled
study, a six-month period before ECE treatment was regard-
ed as internal control to compare to 6 months after ECE treat-
ment. To our knowledge, it is the first clinical trial to inves-
tigate the preventive efficacy of ECE for 6 months after the
end of treatment. We found that ECE significantly reduced
the number of recurrent episodes of UTIs 3.9-fold, as well as
the severity of UTI symptoms, including urgency, painful
voiding and frequency. These effects of ECE may be due to
its enhancement of immune responses, leading to control of
bacterial infection. 
The mechanism of action of ECE is based on its ability to
boost the overall immune system, not on the direct inhibition
of E. coli. However, we found that ECE treatment reduced the
incidence of E. coli in urine cultures, although the difference
was not significant. 
Over the past two decades, ECE has been widely accepted
as an effective immunostimulant, with a good safety record. It
was reported that most patients treated with ECE experience
minor adverse events as frequently as patients in the placebo
group. The most frequent adverse events were headache and
gastrointestinal side effects, but there were no safety concerns
with regard to laboratory variables and clinical signs (23).
Our study also confirmed the safety and efficacy of ECE
during and for 6 months after the end of treatment. Repeti-
tive use of antibiotics has been found to suppress the immune
system. Patients with frequent UTI recurrences require an
immunostimulating drug to prevent further depression of
the immune system. The immunostimulant ECE has been
shown to effectively suppress the recurrence of cystitis with
resultant decrease in severity of UTI symptoms. Our study
demonstrates the efficacy and safety of ECE in the prophy-
lactic treatment of chronically recurrent cystitis.
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